Ibuprofen has a negative impact on the testicles of young men, a study published Monday in the journal Proceedings of the National Academy of Sciences found.
When taking ibuprofen in doses commonly used by athletes, a small sample of young men developed a hormonal condition that typically begins, if at all, during middle age. This condition is linked to reduced fertility.
Black women with a relatively common form of hair loss may also face a high risk for developing fibroids, a new study suggests.
Fibroids are fibrous growths that develop in the lining of the womb. About 80 to 90 percent of black women (and 70 percent of white women) develop fibroids by the time they're 50. In nearly all cases these growths are benign (noncancerous).
Researchers reviewed four years of data on more than 487,000 adult black women. This included data on a hair loss condition known as central centrifugal cicatricial alopecia (CCCA).
Death rates for patients undergoing surgeries in Africa are double the global average even though they tend to be younger, scientists said, adding that many deaths were likely preventable. According to a study published in the Lancet medical journal, scientists said contributory factors include few specialists, poor hospital infrastructure and a lack of post-operative monitoring.
A consultant gastroenterologist and pathologist at the Aminu Kano Teaching Hospital (AKTH), Dr Yusuf Maisuna Abdulkadir has attributed the high spread and fatality rate among Nigerians suffering from hepatitis, a disease of the liver to ignorance. He was quoted by Dailytrust as saying;
According to a new research, having sex increases the chance of suffering a heart attack.
Scientists have revealed that patients are twice as likely to suffer a heart attack one hour after sex than those who do not have sex.
For those who do little or no exercise, the risk increases four-fold. The results contrast with other studies which have shown that men actually improve their health by having regular sex.
A new drug that targets a genetic flaw common to most cancer cells is showing potency against many tumor types.
The preliminary trial of a drug called ulixertinib was conducted with 135 patients who had already failed treatments for one of a variety of advanced, solid tumors.
Researchers led by Dr. Ryan Sullivan, of Massachusetts General Hospital, said ulixertinib did seem to spur at least a "partial response" to the therapy or "disease stabilization," regardless of cancer type.
